Enhanced Immunogenicity of Engineered HER2 Antigens Potentiates Antitumor Immune Responses

For cancer vaccines, the selection of optimal tumor-associated antigens (TAAs) that can maximize the immunogenicity of the vaccine without causing unwanted adverse effects is challenging. In this study, we developed two engineered Human epidermal growth factor receptor 2 (HER2) antigens, K965 and K1...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeon, Insu, Lee, Jeong-Mi, Shin, Kwang-Soo, Kang, Taeseung, Park, Myung Hwan, Seo, Hyungseok, Song, Boyeong, Koh, Choong-Hyun, Choi, Jeongwon, Shin, Young Kee, Kim, Byung-Seok, Kang, Chang-Yuil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563373/
https://www.ncbi.nlm.nih.gov/pubmed/32707803
http://dx.doi.org/10.3390/vaccines8030403

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563373/
https://www.ncbi.nlm.nih.gov/pubmed/32707803
http://dx.doi.org/10.3390/vaccines8030403

Ejemplares similares